Speed Is Not the Same as Trust: What Foundayo’s CNPV Approval Means for HCP Engagement
Sriram Subramanian
·
4 minute read
On April 1, 2026, Eli Lilly’s Foundayo (orforglipron) became the fifth product approved under the FDA’s Commissioner’s National Priority Voucher program — and the first new molecular entity to clear that bar. The FDA called it “the fastest approval of a new molecular entity since 2002.” That’s a remarkable regulatory achievement. It’s also a stress test for how the industry engages the physicians who will actually prescribe it.
The CNPV program, launched in June 2025, compresses the traditional 6-to-10-month drug review into 1 to 2 months for products the Commissioner designates as aligned with national interests — a broad set of priorities including public health crises, unmet needs, manufacturing onshoring, and drug affordability. FDA Commissioner Marty Makary has called it a “game changer,” and by March 2026, 18 vouchers had already been awarded.
But the program has generated significant criticism — and that criticism doesn’t stay inside the Beltway. Two members of Congress have cited “deep concerns” about political favoritism and rushed reviews. Scholars at Harvard’s Petrie-Flom Center have warned that the program’s opacity creates real legal vulnerability, from competitive lawsuits to failure-to-warn patient litigation. The FDA has now scheduled a public hearing for June 12 to solicit feedback on the program. When a regulator opens its own initiative to public scrutiny nine months after launch, the message is clear: the science of trust hasn’t kept pace with the science of speed.
Here is what this means for manufacturers:
- Prescriber skepticism is a launch risk. Every drug that passes through CNPV carries an invisible asterisk in the minds of cautious clinicians — not because the underlying data isn't rigorous, but because physicians are acutely sensitive to process integrity. That doubt travels with the prescription, shapes patient conversations, and surfaces in formulary discussions. No launch campaign reverses it.
- Scientific communication must fill the trust gap. Manufacturers cannot outsource credibility to the FDA's approval stamp when that stamp itself is under scrutiny. Field teams need transparent, evidence-first narratives that answer the questions a rigorous clinician asks before writing a script: What does the safety data show? How does this compare to a standard review? Why was this a national priority?
- Real-time HCP intelligence remains a competitive advantage. Understanding how prescribers are actually receiving a CNPV-approved drug — before skepticism hardens into formulary resistance — is no longer optional. Manufacturers who invest in this intelligence early will protect commercial performance. Those who wait will spend launch budgets overcoming doubt that could have been anticipated.
Every drug that passes through CNPV carries an invisible asterisk in the minds of cautious clinicians. Not because the underlying data isn’t rigorous — Lilly’s ATTAIN clinical program is — but because physicians are acutely sensitive to process integrity. When prescribers question whether a review was scientifically exhaustive or politically expedited, that doubt travels with the prescription. It shapes patient conversations. It surfaces in formulary discussions. No launch campaign reverses it.
Our experience serving top pharma clients has taught us that gathering systematic HCP perception data on CNPV-approved products is the next crucial step. The program is still young, the approvals are accelerating, and the research infrastructure to track prescriber attitudes at this level of granularity hasn’t caught up. That gap is itself the strategic signal — manufacturers need this intelligence now, before the skepticism hardens.
From years of listening to physicians across multiple therapeutic areas, we’ve also learned companies that outperform in moments of regulatory uncertainty are those that go deeper on scientific communication, not broader. Manufacturers will need to genuinely understand what physicians need to trust CNPV-approved products. The CNPV era has made earning that trust manufacturers’ responsibility in a way it never was before.
“Speed gets a drug to approval. Trust gets it to adoption.”
References
1. Kansteiner, F. (April 1, 2026). “Lilly answers Novo’s GLP-1 pill with highly anticipated FDA nod for Foundayo.” FiercePharma. https://www.fiercepharma.com/pharma/lilly-answers-novos-glp-1-pill-highly-anticipated-fda-nod-foundayo
2. Sagonowsky, E. (March 23, 2026). “FDA solicits feedback on national priority voucher pilot.” FiercePharma. https://www.fiercepharma.com/pharma/fda-solicits-feedback-controversial-national-priority-voucher-review-pathway
3. Sipes, G. (March 13, 2026). “Hazards Ahead for FDA’s Drug Review Process.” Petrie-Flom Center, Harvard Law School. https://petrieflom.law.harvard.edu/2026/03/13/hazards-ahead-for-fdas-drug-review-process/
4. McKenzie, H. (March 23, 2026). “9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty.” BioSpace.
https://www.biospace.com/fda/9-months-in-fdas-new-priority-voucher-program-still-clouded-with-uncertainty
5. Taylor, P. (March 23, 2026). “FDA seeks input into ‘opaque’ priority voucher scheme.” pharmaphorum. https://pharmaphorum.com/news/fda-seeks-input-opaque-priority-voucher-scheme
6. Baker, M. (December 5, 2025). “Whither the FDA’s Commissioner’s National Priority Voucher?” American Action Forum. https://www.americanactionforum.org/weekly-checkup/whither-the-fdas-commissioners-national-priority-voucher/
7. (December 19, 2025). “FDA voucher program has led to political interference in drug reviews, staffers say.” STAT News [subscription required].
https://www.statnews.com/2025/12/19/fda-voucher-program-political-interference/
Frequently Asked Questions
What is the FDA’s Commissioner’s National Priority Voucher (CNPV) program, and why is it controversial?
The CNPV program, launched in June 2025, accelerates FDA drug reviews from the standard 6–10 months to just 1–2 months for therapies the Commissioner designates as aligned with U.S. national interests. While FDA Commissioner Marty Makary has defended it as a “game changer” for patients, the program has drawn bipartisan criticism. Lawmakers have raised concerns about political favoritism in drug selection, rushed safety reviews, and a lack of congressional authorization. Legal scholars at Harvard’s Petrie-Flom Center have warned that the program’s opacity exposes approved drugs to failure-to-warn litigation and competitive legal challenges. As of March 2026, 18 vouchers had been awarded and a public hearing was scheduled for June 12, 2026.
How does CNPV drug approval affect physician trust and prescribing decisions?
CNPV-approved drugs face a unique trust gap with physicians. Because the 1–2 month review compresses the scientific evaluation period that clinicians rely on to build confidence in a new therapy, prescribers may question whether safety and efficacy data received adequate scrutiny. Research consistently shows that physicians’ trust in a drug is inseparable from their trust in the approval process itself. When political interference is perceived — as it has been with CNPV — prescribers may be more cautious at the point of prescribing, more demanding of clinical dialogue with manufacturer representatives, and more likely to defer to established therapies already on formulary. This dynamic requires manufacturers to proactively and transparently communicate their clinical evidence base, going beyond standard launch materials.
What should pharma manufacturers do to improve HCP engagement for CNPV-approved drugs?
Manufacturers launching CNPV-approved drugs should treat physician trust as a first-order commercial challenge, not a communications afterthought. Three priorities stand out: First, invest in real-time HCP perception research to understand how prescribers are receiving the drug and the regulatory pathway — before skepticism hardens into formulary resistance. Second, arm field teams with transparent, science-first clinical narratives that directly address questions physicians are likely to ask about review rigor. Third, distinguish the drug’s clinical evidence from the regulatory debate — the two are not the same, and conflating them undermines credibility. In an era where the FDA’s own review process is under scrutiny, manufacturer-HCP trust must be built independently of regulator confidence.
Get in Touch
